Search Results

Press Releases

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients’ Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

February 19, 2025

·

5 min read

FDA

QOL Medical, LLC receives FDA approval of Sucraid® (sacrosidase) Oral Solution single-use containers for patients with Congenital Sucrase-Isomaltase Deficiency (CSID)

QOL Medical, LLC, a ground-breaking, rare disease pharmaceutical company, announced today that the United States (U.S.) Food & Drug Administration (FDA) approved Sucraid® single-use containers for patients more than 33 lb (15 kg) with Congenital Sucrase-Isomaltase Deficiency (CSID).

September 6, 2022

·

3 min read

Business

QOL Medical, LLC Selects Optum Frontier Therapies as an Exclusive Pharmacy Partner to Best Support Congenital Sucrase-Isomaltase Deficiency (CSID) Patients on Sucraid® (sacrosidase) Oral Solution

QOL Medical, LLC announced today it has selected Optum Frontier Therapies as its new pharmacy partner to support CSID patients nationwide being treated with Sucraid® (sacrosidase) Oral Solution.

April 15, 2022

·

4 min read

Press Releases

Neuspera Medical Announces Landmark Six-Month Clinical Trial Results for the First Battery-Free Percutaneous Sacral Neuromodulation (pSNM) System for Urgency Urinary Incontinence Management

February 27, 2025

·

5 min read

Genetown

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new analyses on amyloid-related imaging abnormalities with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life, from the results of Eisai’s Phase 3 Clarity AD study of lecanemab, an anti-amyloid-β protofibril* antibody, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases annual meeting AD/PD™.

March 30, 2023

·

13 min read

Press Releases

Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco

January 9, 2025

·

2 min read

Press Releases

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

March 3, 2025

·